GlassScriptPhysician profile
Jerry V Mosley
NPI 1821106592
$14,373.16
in general payments reported to CMS, 2019-2025
45 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,891 · 2020: $1,542 · 2021: $2,340 · 2022: $2,442 · 2023: $2,182 · 2024: $2,803 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,158.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,030.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,448.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,120.17 | 2019-2024 | Xarelto |
| Abbvie INC. | $935.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $764.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $714.97 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $672.67 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.72 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $651.84 | 2019-2025 | Trintellix |
| Mdd US Operations, LLC | $611.88 | 2022-2024 | Gocovri, Gocovri, Apokyn |
| Esperion Therapeutics, INC. | $477.38 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $440.09 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.72 | 2019-2024 | Xifaxan |
| Amgen INC. | $351.83 | 2019-2021 | |
| Exact Sciences Corporation | $304.25 | 2023-2025 | Cologuard Collection Kit |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $303.13 | 2019-2024 | Livalo, Seglentis |
| Lilly USA, LLC | $293.94 | 2019-2024 | Jardiance, Zepbound, Emgality |
| Allergan, INC. | $238.00 | 2019-2020 | |
| Abbott Laboratories | $219.18 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $200.56 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $192.31 | 2019-2023 | Linzess |
| Lundbeck LLC | $180.14 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $144.68 | 2019-2020 | |
| Dexcom, INC. | $126.46 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $125.48 | 2019-2023 | Myrbetriq, Veozah |
| Radius Health, INC. | $116.41 | 2019-2021 | |
| Ardelyx, INC. | $69.09 | 2024 | Ibsrela |
| Alkermes, INC. | $66.48 | 2022-2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $63.62 | 2019-2022 | |
| Corcept Therapeutics | $60.82 | 2023-2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $56.73 | 2022 | |
| Antares Pharma, INC. | $54.60 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Eisai INC. | $49.78 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $46.62 | 2024 | Voquezna |
| Acadia Pharmaceuticals INC | $46.25 | 2024 | Nuplazid |
| Scilex Pharmaceuticals INC. | $29.21 | 2022 | |
| Hikma Pharmaceuticals USA | $29.13 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $16.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.62 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Vifor Pharma, INC. | $13.56 | 2025 | Zemaira |
| Genentech USA, INC. | $13.07 | 2022 | |
| Therapeuticsmd, INC. | $12.88 | 2019 | |
| Hologic Sales and Service, LLC | $12.71 | 2019 | |
| Glaxosmithkline, LLC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.